N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors

1. A compound of Formula IIa:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is methyl or ethyl;

R 2 is selected from C 1-6 alkyl, —O—(C 1-6 alkyl), —O—(C 1-4 alkylene) n -(4-7 membered heterocycloalkyl), and phenyl; wherein said phenyl is optionally substituted by 1, 2, 3, or 4 independently selected halo groups;

Cy 3 is selected from phenyl, a piperidine ring, a pyrrolidin-2-one ring, a 1,3-oxazolidin-2-one ring, an isoxazole ring, a pyrazole ring, a tetrazole ring, a triazole ring, a pyridine ring, a pyrimidine ring, an azetidine ring, a pyrrole ring, a tetrahydrofuran ring, and a morpholin-2-one ring; each of which is optionally substituted with 1, 2, 3, or 4 independently selected R 3a groups;

R 4 is selected from H, halo, C 1-3 alkyl, CN, cyano-C 1-6 alkyl, and C 1-6 haloalkyl;

R 5 is selected from C 1-3 alkyl, halo, and CN;

each R 3a is independently selected from halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, (4-7 membered heterocycloalkyl)-C 1-3 alkyl, (5-6 membered heteroaryl)-C 1-3 alkyl, OR a , C(O)R b , C(O)OR a , C(O)NR c R d , NR c R d , NR c C(O)R b , and S(O) 2 R b ; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 groups independently selected from OH, CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, cyano-C 1-6 alkyl, HO—C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C 3-7 cycloalkyl;

each R a , R c , and R d is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from OH, CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, and amino;

each R b is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl; each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from OH, CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, and amino; and

n is 0 or 1.

2. The compound of claim 1 , which is 4-{3-chloro-6-methoxy-2-methyl-5-[1-(9H-purin-6-ylamino)ethyl]phenyl}pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.

3. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

4. A composition comprising a compound according to claim 2 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

5. A method of treating asthma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

6. A method of treating brain cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

7. A method of treating colon cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

8. A method of treating bladder cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

9. A method of treating asthma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

10. A method of treating brain cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

11. A method of treating colon cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.

12. A method of treating bladder cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said treating refers to inhibiting or ameliorating.